rt112/84 (CancerTools Org)
Structured Review
Rt112/84, supplied by CancerTools Org, used in various techniques. Bioz Stars score: 99/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rt112/RT112%2F84/custom%40153250%4010%2E64898%2F2026%2E10%2E05%2E756638
Average 99 stars, based on 13 article reviews
Images
Related Articles
Cell Culture:Article Title: A novel quinoline and manganese-based carbon monoxide-releasing molecule for intravesical therapy of bladder cancer. Article Snippet: Funding information Jiaxing Medical Key Subject Funding of Zhejiang Province, Grant/Award Number: 2023-ZC-013; the Jiaxing Key Laboratory of Precise Diagnosis and Treatment of Urological Tumor, Grant/Award Number: 2020-mnzdsys; National Natural Science Foundation of China, Grant/Award Number: 82104197; Natural Science Foundation of Zhejiang Province, Grant/Award Number: LY23B010002; Jiaxing University, Grant/Award Number: CD70623036 Abstract Background and Purpose: Bladder cancer remains a significant burden on public health globally.. Carbon monoxide (CO) has emerged as a promising therapeutic agent for cancers because of its key role in inducing mitochondrial dysfunction and metabolic reprogramming in cancer cells; however, its clinical translation has been hindered by systemic toxicity because of its binding to haemoglobin, which is avoided by localised intravesical therapy via the bladder.. This study aimed to develop and characterise a novel manganese(I)-based CO releasing molecular MnCORM as a therapeutic agent against bladder cancer. |
